The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE): Clinical implications of recurrent genomic alterations in lethal prostate cancer.
 
Ryan Rebernick
No Relationships to Disclose
 
Liat Hammer
No Relationships to Disclose
 
Matthew McFarlane
No Relationships to Disclose
 
Thomas Westbrook
No Relationships to Disclose
 
Munna Hazime
No Relationships to Disclose
 
Tanya Hammoud
No Relationships to Disclose
 
Pin-en Chiu
No Relationships to Disclose
 
Xavier Owens
No Relationships to Disclose
 
Yi-Mi Wu
No Relationships to Disclose
 
Dan Robinson
No Relationships to Disclose
 
Daniel Spratt
No Relationships to Disclose
 
Ajjai Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
William Jackson
Research Funding - Janssen (Inst)
 
Zachery Reichert
Consulting or Advisory Role - AstraZeneca; Janssen Oncology
Research Funding - AstraZeneca (Inst)
Expert Testimony - Huff Bowell Bailey
 
Joshi Alumkal
Consulting or Advisory Role - FibroGen; ORIC Pharmaceuticals
Research Funding - NCCN/Pfizer; Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - ORIC Pharmaceuticals
 
Arul Chinnaiyan
Stock and Other Ownership Interests - Ascentage Pharma; EdenRoc Sciences; Esanik Therapeutics Inc; Flamingo Therapeutics; GenePath Dx; LynxDx; RAAPTA; Tempus, Inc
Consulting or Advisory Role - Ascentage Pharma; Esanik Therapeutics; Flamingo Therapeutics; LynxDx; Proteovant; RAAPTA; Tempus, Inc
Patents, Royalties, Other Intellectual Property - GenomeDx- intellectual property, patents; LynxDx- Patents; Tempus Inc,-Intellectual Property
Travel, Accommodations, Expenses - RAAPTA
Other Relationship - Tempus
 
Marcin Cieslik
No Relationships to Disclose
 
Robert Dess
Consulting or Advisory Role - Janssen